Fangsheng Pharmaceutical(SH:603998) KAIYUAN SECURITIES·2025-08-29 08:15Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 834 million yuan in H1 2025, a year-on-year decrease of 8.35%, while the net profit attributable to the parent company increased by 23.67% to 169 million yuan [4] - The company maintains a strong focus on innovative traditional Chinese medicine, which is expected to enhance its long-term competitive edge [4] - The forecast for net profit attributable to the parent company for 2025-2027 is 308 million, 378 million, and 457 million yuan respectively, with corresponding EPS of 0.70, 0.86, and 1.04 yuan [4] Financial Performance Summary - In H1 2025, the gross profit margin was 70.30%, a decrease of 2.36 percentage points, while the net profit margin increased by 5.06 percentage points to 19.96% [4] - The sales expense ratio decreased by 8.21 percentage points to 33.58%, while the R&D expense ratio increased by 1.42 percentage points to 8.16% [4] - The company reported a significant increase in revenue from cardiovascular drugs, which reached 276 million yuan, up 16.05% [5] Product Development and Innovation - The company plans to acquire the patent rights for a Class 1 innovative chemical drug, IMM-H024, for 80 million yuan, which is expected to strengthen its innovative drug pipeline [6] - The "Yangxue Qufeng Zhitong Granules" is the company's third innovative traditional Chinese medicine product, which has passed preliminary review for inclusion in the national basic medical insurance directory [6]